Dr. Mitchell is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 Pasteur Dr
Stanford, CA 94305Phone+1 650-723-4000Fax+1 650-724-5203
Education & Training
University of MichiganResidency, Internal Medicine, 1976 - 1977- University of MichiganFellowship, Hematology and Medical Oncology, 1977
University of WashingtonResidency, Internal Medicine, 1970 - 1973- University of Washington School of MedicineInternship, Transitional Year, 1969 - 1970
Harvard Medical SchoolClass of 1969
Certifications & Licensure
CA State Medical License 2006 - 2025
NC State Medical License 1992 - 2021
MI State Medical License 1975 - 1992- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2002-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
- Join now to see all
Publications & Presentations
PubMed
- 17 citationsRegulation of human deoxycytidine kinase expression.Beverly S. Mitchell, James J. Song, Earnest E. Johnson, Everett H. Chen, Jennifer S. Dayton
Advances in Enzyme Regulation. 1993-01-01 - 109 citationsCloning and expression of human deoxycytidine kinase cDNA.E G Chottiner, Donna S. Shewach, Nabanita S. Datta, Elizabeth Ashcraft, D Gribbin
Proceedings of the National Academy of Sciences of the United States of America. 1991-02-15 - 105 citationsResistance to 1-beta-D-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene.Janet K. Owens, Donna S. Shewach, Buddy Ullman, Beverly S. Mitchell
Cancer Research. 1992-05-01
Press Mentions
ASH Presents Honorific Awards, Immunotherapy Researchers Receive Nobel Prize in Medicine, and MoreDecember 1st, 2018
Steven Artandi Selected as New Director of Stanford Cancer InstituteOctober 23rd, 2018
Steven Artandi Tapped to Lead Stanford Cancer InstituteOctober 1st, 2018- Join now to see all
Grant Support
- Project Senior LeadersNational Cancer Institute2011
- Planning And EvaluationNational Cancer Institute2011
- Developmental FundsNational Cancer Institute2011
- Stanford University Cancer CenterNational Cancer Institute2008–2011
- Cancer Stem Cells And Radiotherapy: New Approaches To RadiosensitizationNational Cancer Institute2009–2010
- 2009 Aaci Annual MeetingNational Cancer Institute2009
- Core--Protocol-Specific ResearchNational Cancer Institute2005–2009
- Role Of Hpso4 In Double Strand Break RepairNational Institute Of General Medical Sciences2007
- Inosine Monophosphate Dehydrogenase: Regulation And FunctionNational Cancer Institute2006–2007
- Role Of Hpso$ In Double Strand Break RepairNational Institute Of General Medical Sciences2006
- Role Of Hpso$ In Double Strand Break RepairNational Institute Of General Medical Sciences2005
- Inosine Monophosphate Dehydrogenase: Regulation And FunctionNational Cancer Institute2004–2005
- Role Of Hpso4 In Double Strand Break RepairNational Institute Of General Medical Sciences2004
- Research Fellowships In Hematology/OncologyNational Heart, Lung, And Blood Institute1996–2004
- Nucleoside And Nucleotide Metabolizing EnzymesNational Cancer Institute1995–2004
- Inosine Monophosphate Dehydrogenase: Regulation/FunctionNational Cancer Institute2003
- Refractory Hematologic Malignancies (Compound 506)National Center For Research Resources1999–2002
- Inosine Monophosphate Dehydrogenase--Reg And FunctionNational Cancer Institute1998–2002
- Study Of 506U78 In Patients With Refractory Hematologic CancerNational Center For Research Resources1998–1999
- Phase 1 Study--Refractory Hematologic Malignancies (Compound 506)National Center For Research Resources1996–1997
- IMP Dehydrogenase--Regulation And FunctionNational Cancer Institute1994–1997
- Icn001--Phase II Study Of Patients With CML In Blast Crisis Treated W/ TiazofurinNational Center For Research Resources1996
- Terminal Transferase In Mammalian Hemopoietic TissueNational Cancer Institute1994–1995
- Inhibitors Of Purine Nucleoside PhosphorylaseNational Cancer Institute1991–1994
- Overproduction Of Adenosine Deaminase In ErythrocytesNational Institute Of Allergy And Infectious Diseases1991–1993
- Overproduction Of Adenosine Deaminase In ErythrocytesNational Institute Of Allergy And Infectious Diseases1986–1991
- Inhibitors Of Purine Nucleoside PhosphorylaseNational Cancer Institute1985–1991
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
